Ignite Creation Date:
2024-05-06 @ 2:54 PM
Last Modification Date:
2024-10-26 @ 1:39 PM
Study NCT ID:
NCT04464408
Status:
COMPLETED
Last Update Posted:
2021-11-05
First Post:
2020-06-28
Brief Title:
Favipiravir Therapy in Adults With Mild COVID-19
Sponsor:
King Abdullah International Medical Research Center
Organization:
King Abdullah International Medical Research Center
Study Overview
Official Title:
A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Avi-Mild
Brief Summary:
Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase It acts as a purine analogue which selectively inhibits viral RNA-dependent RNA polymerase RdRps It has the characteristic of acting on RNA viruses including Ebola and Coronaviruses especially novel coronavirus 2019-nCoV The purpose of this study is to evaluate the clinical efficacy and safety of Favipiravir in comparison to placebo in the treatment of mild COVID-19 cases It is a Multicenter randomized double-blinded parallel-group trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None